Leerink Partnrs Analysts Lower Earnings Estimates for TMO

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Stock analysts at Leerink Partnrs dropped their Q1 2025 EPS estimates for shares of Thermo Fisher Scientific in a note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $5.43 for the quarter, down from their prior estimate of $5.59. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $21.68 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q2 2025 earnings at $5.62 EPS, Q3 2025 earnings at $5.64 EPS, Q4 2025 earnings at $6.49 EPS, FY2025 earnings at $23.18 EPS and FY2026 earnings at $25.36 EPS.

A number of other research analysts have also issued reports on the stock. Evercore ISI lowered their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Sanford C. Bernstein dropped their price objective on Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating on the stock in a research note on Thursday, October 24th. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Barclays dropped their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a research report on Wednesday, October 23rd. Finally, Bank of America reduced their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research report on Friday. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $652.30.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $3.37 during midday trading on Monday, hitting $530.26. 2,370,347 shares of the company traded hands, compared to its average volume of 1,543,948. The business has a 50 day simple moving average of $550.39 and a 200-day simple moving average of $573.77. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a twelve month low of $493.30 and a twelve month high of $627.88. The stock has a market capitalization of $202.82 billion, a price-to-earnings ratio of 33.03, a price-to-earnings-growth ratio of 3.54 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business's revenue was up .2% compared to the same quarter last year. During the same period last year, the company earned $5.69 earnings per share.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after purchasing an additional 127,564 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Thermo Fisher Scientific by 11.4% during the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after acquiring an additional 995 shares during the period. Greenwood Gearhart Inc. raised its position in shares of Thermo Fisher Scientific by 9.8% during the 3rd quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock valued at $12,730,000 after acquiring an additional 1,837 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 6.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock worth $87,093,000 after purchasing an additional 8,180 shares during the last quarter. Finally, Summit Trail Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 29.2% during the third quarter. Summit Trail Advisors LLC now owns 5,378 shares of the medical research company's stock worth $3,329,000 after purchasing an additional 1,214 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock worth $25,954,465 over the last three months. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.